Response to Office Action of: 06/27/2007

Response Dated: 09/27/2007

Title: Nasal Peptide Pharmaceutical Formulation

App. No.: 10/516,613

Inventor: Paolo A. Veronesi et al.

Examiner: Maury A. Audet

Amendment(s) to the Specification

Please replace paragraph [0040] of the present application, as published, with the

following rewritten paragraph:

[0040] In fact it has been unexpectedly noticed that one of the most striking

characteristics of THAM in the instant invention is that this organic hydrogen-ion

acceptor produces a marked biological activity in vivo and physiologically and reversibly

depolarizes the nasal mucosa epithelial cell membranes, thus enhancing the active

process of nasal peptide absorption. Furthermore, TRAM THAM, contrarily to other

amines, produces such desirable effects at concentrations where other amines exhibit

significant toxicity problems.

Please replace paragraph [0042] of the present application, as published, with the

following rewritten paragraph:

[0042] In other words, it has been experimentally observed that TRAM THAM

prevents the oxidation of the disulphide bridges between the thioamino acids of the

nasal peptides, thus unexpectedly stabilizing the therapeutically effective amount of the

nasal peptide of the pharmaceutical formulation.

Please replace paragraph [0045] of the present application, as published, with the

following rewritten paragraph:

[0045] (a1) In a convenient amount of distilled water is dissolved in a suitable

container the adequate quantity of TRAM THAM and optionally of methyl or/and propyl

p-hydroxybenzoate, hydrochloric or citric acid, cysteine and stirred until complete

dissolution;

3